Metrics as of 10/13/2026, 06:54 PM (Berlin time), refresh in progress.
PepGen Stock
PepGen Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- James McArthur
- Employees
- 57
- Market cap
- $162 M
- IPO
- 06/05/2022
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of…
PepGen stock: price history
1D
-7.0%
1W
-3.1%
1M
-21.7%
6M
+35.2%
YTD
-64.3%
1Y
-49.2%
2Y
-73.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~25% stronger price swings than usual
Ask the agents about PepGen
Analyst assessment of PepGen
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
0
STRONG BUY
5
BUY
0
HOLD
1
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 09/09/2026
PepGen stock metrics
P/E
-1.56
P/B
1.36
EV/EBITDA
-2.2
RETURN ON EQUITY
-14.9%
NET MARGIN
0.0%
DEBT/EQUITY
0.13
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
52.1%
FLOAT SHARES
36,046,153
AVG. DAILY VOLUME (30D)
783,846
Insider transactions (SEC)
Kasraian Kasra
Institutional holders
Comparable stocks
Frequently asked questions about PepGen stock
What does PepGen do?
PepGen Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is James McArthur, the company employs around 57 people.
The IPO was on 06/05/2022; the stock trades on NASDAQ under the ticker PEPG.
What do analysts say about PepGen stock?
6 analysts rate the stock, the consensus is Buy (as of 09/09/2026).
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does PepGen report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 25% stronger than usual.
Does PepGen pay a dividend?
No, PepGen currently does not pay a dividend.
Which stocks are comparable to PepGen?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get PepGen stock analyzed?
Clicking "Analyze stock" lets five strategies assess PepGen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.